Antibody-based therapeutics show great promise, especially against cancer. Pipeline 2 explores the emerging field of next-generation antibody therapeutics, including Antibody-Drug Conjugates, Bispecific Antibody Therapeutics and engineering antibodies that fight cancer. The weeklong Antibody Therapeutics pipeline reveals R&D strategies, clinical results and efficacy data for these promising molecules.
Conferences Include:
January 18-19
Next-Generation Cancer Immunotherapies
January 19-20
Antibody-Drug Conjugates
January 21-22
Bispecific Antibody Therapeutics